

# HQIC Office Hours – Infection Prevention Chats

**Welcome!**

- Please ask any questions in the chat
- Please actively participate in discussions
- Lines will be muted upon entry

**We will get started shortly!**

# Making Health Care Better *Together*

## **COLLABORATORS:**

Alabama Hospital Association  
Alliant Health Solutions  
Comagine Health  
Georgia Hospital Association  
KFMC Health Improvement Partners  
Konza

## Hospital Quality Improvement

# Welcome from all of us!



# Facilitator

---



**Amy Ward, MS, BSN, RN, CIC, FAPIC**

**Patient Safety Manager**

Amy is a registered nurse with a diverse background in acute care nursing, microbiology, epidemiology and infection control. She is passionate about leading and mentoring new and future infection preventionists in their career paths.

Amy loves to ride bikes, run and be outdoors!

Contact: [Amy.Ward@Allianthealth.org](mailto:Amy.Ward@Allianthealth.org)

# Format for IP Chats

---

- Sessions are not recorded and minutes are not taken
- Open forum networking events to:
  - Build knowledge
  - Share experience
  - Provide IP support

# IP Chats – Your feedback Is Requested

---

Please drop in to chat your preference:

1. Would you prefer IP Chats as a quarterly meeting that covers pertinent IP Topics?
2. Would you be willing to participate by submitting and describing a case study or how you successfully reduced HAIs in your facility?
3. Would you prefer to schedule 1:1 calls with a seasoned IP SME as needed rather than having scheduled meetings?

# COVID-19 Updates

---

The CDC updated its infection prevention and control (IPC) guidance for U.S. health care settings on September 23 to [reflect the high levels of vaccine- and infection-induced immunity and the availability of effective treatments and prevention tools.](#)

- The update provides additional protection measures for patients and health care workers, especially in hospitals and nursing homes, where COVID-19 is more likely to spread quickly or cause severe disease if introduced.

[Community Transmission](#) remains the metric to guide select actions in health care settings.

- Community Transmission allows for earlier intervention before there is a strain on the health care system and better protects the individuals seeking medical care in these settings.

[Interim Infection Prevention and Control Recommendations for Healthcare Personnel During the Coronavirus Disease 2019 \(COVID-19\) Pandemic](#)

[Interim Guidance for Managing Healthcare Personnel with SARS-CoV-2 Infection or Exposure to SARS-CoV-2 | CDC](#)

[Strategies to Mitigate Healthcare Personnel Staffing Shortages | CDC](#)

# Key Updates to COVID-19 Infection Control Guidance

---

- Vaccination status is no longer used to inform source control, screening testing, or post-exposure recommendations
- Updated source control recommendations
- Updated universal PPE use recommendations
- Updated testing frequency to detect potential variants with shortened incubation periods and address the risk for false negative Ag tests in asymptomatic individuals
- Clarified screening testing of asymptomatic personnel is at the discretion of the facility
- Asymptomatic people no longer require transmission-based precautions after close contact
- Infection prevention guidance now applies to all health care settings, no longer setting specific

# Source Control

- When SARS-CoV-2 [Community Transmission](#) levels are high, source control is recommended for everyone in a health care setting when they are in areas of the facility where they could encounter patients.
  - HCP could choose not to wear source control when they are in well-defined areas that are restricted from patient access (e.g., staff meeting rooms) if they do not otherwise meet the criteria described below and [Community Levels](#) are not also high. When [Community Levels](#) are high, source control is recommended for everyone.
- When SARS-CoV-2 [Community Transmission](#) levels are **not** high, health care facilities could choose not to require universal source control.
  - However, even if source control is not universally required, it remains recommended for individuals in health care settings who:
    - Have suspected or confirmed SARS-CoV-2 infection or other respiratory infection (e.g., those with a runny nose, cough, sneeze)
    - Had [close contact](#) (patients and visitors) or a [higher-risk exposure](#) (HCP) with someone with SARS-CoV-2 infection for 10 days after their exposure
    - Reside or work on a unit or area of the facility experiencing a SARS-CoV-2 outbreak; universal use of source control could be discontinued as a mitigation measure once no new cases have been identified for 14 days
    - Have otherwise had source control recommended by public health authorities



# Universal Use of PPE

---

- When COVID-19 is not suspected, follow standard precautions (and transmission-based precautions when required)
- When community transmission levels increase, consider expanding the use of respirators and eye protection in certain encounters or areas
  - Aerosol generating procedures
  - Surgical procedures that could produce infectious aerosols (ENT/resp. tract)
  - When patients may be unable to wear source control
  - In poorly ventilated areas
  - To ease implementation, consider implementing the universal use of respirators and eye protection in specific areas when community transmission levels are high

# Duration of Empiric Transmission-Based Precautions

- Symptomatic patients under evaluation for COVID-19
  - Discontinue TBP when a single negative PCR test is confirmed, or
  - Discontinue with negative antigen + negative PCR or second negative antigen 48 hours after the first negative result
- Asymptomatic patients following close contact with someone with COVID-19
  - In general, do not require TBP unless unable to test or wear source control, severe immune compromise, housed in a unit with others who are severely immune compromised, housed in a unit with ongoing transmission
  - When placed in TBP for the reasons above, remove after 10 days if symptoms do not develop; seven days with a negative test between days five through seven
- Confirmed cases
  - At least 10 days post symptom onset with the absence of fever and symptoms improving

# Testing

---

- Symptomatic individuals should receive a viral test as soon as possible regardless of vaccination status
- Asymptomatic patients with close contact should have a series of three tests - 24 hours post-exposure, 48 hours after first negative, and 48 hours after the second negative (e.g., days 1, 3 and 5 post-exposure).
- If implementing a screening testing program, testing decisions should not be based on the vaccination status of the individual being screened.
  - To provide the greatest assurance that someone does not have SARS-CoV-2 infection, if using an antigen test instead of a NAAT, facilities should use three tests, spaced 48 hours apart, in line with [FDA recommendations](#).
  - In general, the performance of pre-procedure or pre-admission testing is at the discretion of the facility.
- Performance of expanded screening testing of asymptomatic HCP without known exposures is at the discretion of the facility.

[Infection Control: Severe acute respiratory syndrome coronavirus 2 \(SARS-CoV-2\) | CDC](#)

# COVID-19 Hospital Data Reporting Changes

---

- NHSN will assume responsibility as the database for COVID-19 hospital data
- On December 31, 2022, the TeleTracking contract will expire, and NHSN will become the new reporting platform
- No changes to other NHSN Modules
- No significant changes to reporting questions as a result of the transition
- Reporting processes will remain the same
- [Steps to Prepare for the transition](#)
  - Facility Enrollment (please do not enroll without confirming with NHSN– most hospitals are already enrolled)
  - NHSN Access
  - [NHSN Org ID Verification](#)
  - NHSN Groups

Questions? Email [NHSN@cdc.gov](mailto:NHSN@cdc.gov) with the subject line “COVID-19 Hospital”

# NHSN COVID-19 Vaccination for HCW Data Reporting

---

- Weekly submission is encouraged
- CMS Quality Reporting Program facilities are required to submit at least one week per month
- Any week of the month can be selected and reported
- Data should be submitted by the end of the quarter as defined by CMS (e.g., November 15, 2022, for Quarter 2 2022 data)
- A week is designated as belonging to the month of the week-end date.
  - Ex. Reporting data for the week of September 27-October 3 is considered as submitting data for a week in October

# COVID-19 Vaccine Update

---

- Pfizer bivalent vaccine is approved for individuals 12 years of age and older
- Moderna bivalent vaccine is approved for individuals 18 years of age and older
- [Use of COVID-19 Vaccines in the U.S. Interim Clinical Considerations](#)
- [Product Info by U.S. Vaccine](#)
- [FAQs for the Interim Clinical Considerations](#)
- [At-a-Glance: COVID-19 Vaccination Schedule for Most People](#)

# COVID-19 Variant Update

---

- All circulating viruses continue to be Omicron viruses, with the BA.5 lineage remaining the prominent circulating virus in the U.S.
- The BF.7 and BA.2.75 sub-lineages were recently added to [COVID Data Tracker](#)
- [Vaccinations in the United States](#)
- [What You Need to Know About Variants](#)

# CIC Study Group

---


- The **Florida Department of Health (DOH) Health Care-Associated Infection (HAI) Prevention Program** would like to invite you to join the newest cohort for the Certification in Infection Control (CIC) Study Group.
- The cohort will meet each Friday, beginning October 7, 2022, for 26 weeks.
- Certification represents your commitment to improving infection control practices and recognizes you as proficient in the field.
- Use the QR code to fill out the registration, and we will send you the Teams invitation to join. If you have any questions, please do not hesitate to contact us at [HAI\\_Program@flhealth.gov](mailto:HAI_Program@flhealth.gov)





# HQIC Goals

---



## Behavioral Health Outcomes & Opioid Misuse

- ✓ Promote opioid best practices
  - ✓ Decrease high dose opioid prescribing and opioid adverse events in all settings
  - ✓ Increase access to behavioral health services
- 



## Patient Safety

- ✓ Reduce risky medication combinations
  - ✓ Reduce adverse drug events
  - ✓ Reduce *C. diff* in all settings
- 



## Quality of Care Transitions

- ✓ Convene community coalitions
- ✓ Identify and promote optical care for super utilizers
- ✓ Reduce community-based adverse drug events

# Making Health Care Better *Together*

## **COLLABORATORS:**

Alabama Hospital Association  
Alliant Health Solutions  
Comagine Health  
Georgia Hospital Association  
KFMC Health Improvement Partners  
Konza

## Hospital Quality Improvement



@alliantqio



@AlliantQIO

**Thank you for joining us!  
How did we do today?**

Alliant Health Solutions



AlliantQIO



This material was prepared by Alliant Health Solutions, a Hospital Quality Improvement Contractor (HQIC) under contract with the Centers for Medicare & Medicaid Services (CMS), an agency of the U.S. Department of Health and Human Services (HHS). Views expressed in this material do not necessarily reflect the official views or policy of CMS or HHS, and any reference to a specific product or entity herein does not constitute endorsement of that product or entity by CMS or HHS. Publication No. 12SOW-AHS-QIN-QIO TO3-HQIC--2662-09/28/22

 **ALLIANT**  
HEALTH SOLUTIONS

**HQIC**  
Hospital Quality Improvement Contractors  
CENTERS FOR MEDICARE & MEDICAID SERVICES  
QUALITY IMPROVEMENT & INNOVATION GROUP